155 related articles for article (PubMed ID: 7670564)
1. Dopamine responsiveness of human prolactinoma cells as determined by the reverse hemolytic plaque assay.
Kojima Y; Arita J; Kuwana N; Kimura F
Endocr J; 1995 Jun; 42(3):355-60. PubMed ID: 7670564
[TBL] [Abstract][Full Text] [Related]
2. Resistance to bromocriptine in prolactinomas.
Pellegrini I; Rasolonjanahary R; Gunz G; Bertrand P; Delivet S; Jedynak CP; Kordon C; Peillon F; Jaquet P; Enjalbert A
J Clin Endocrinol Metab; 1989 Sep; 69(3):500-9. PubMed ID: 2760167
[TBL] [Abstract][Full Text] [Related]
3. Perifusion studies of bromocriptine-treated and untreated macroprolactinomas: effects of dopamine, bromocriptine and TRH.
Bevan JS; Burke CW
Clin Endocrinol (Oxf); 1989 Jun; 30(6):667-80. PubMed ID: 2512041
[TBL] [Abstract][Full Text] [Related]
4. Hormone secretion by cell culture of human GH-PRL secreting pituitary adenomas: effects of bromocriptine.
Lei T; Bai X; Liu K; Hu W; Xue D; Jiang X
J Tongji Med Univ; 1998; 18(3):161-3. PubMed ID: 10806816
[TBL] [Abstract][Full Text] [Related]
5. DNA synthesis by pituitary tumours, with reference to plasma hormone levels and to effects of bromocriptine.
Lloyd HM; Jacobi JM; Willgoss DA
Clin Endocrinol (Oxf); 1995 Jul; 43(1):79-85. PubMed ID: 7641414
[TBL] [Abstract][Full Text] [Related]
6. Abnormal dopamine sensitivity in some human prolactinomas.
Pellegrini I; Costa R; Grisoli F; Jaquet P
Horm Res; 1989; 31(1-2):19-23. PubMed ID: 2722137
[TBL] [Abstract][Full Text] [Related]
7. Zinc and bromocriptine long-term administration in patients with prolactinomas: effects on prolactin and thymulin circulating levels.
Travaglini P; Mocchegiani E; De Min C; Re T; Fabris N; Faglia G
Int J Neurosci; 1991 Jul; 59(1-3):119-25. PubMed ID: 1774132
[TBL] [Abstract][Full Text] [Related]
8. Hyperprolactinemia and prolactinoma.
Romijn JA
Handb Clin Neurol; 2014; 124():185-95. PubMed ID: 25248588
[TBL] [Abstract][Full Text] [Related]
9. Interferon-alpha-2a is a potent inhibitor of hormone secretion by cultured human pituitary adenomas.
Hofland LJ; de Herder WW; Waaijers M; Zuijderwijk J; Uitterlinden P; van Koetsveld PM; Lamberts SW
J Clin Endocrinol Metab; 1999 Sep; 84(9):3336-43. PubMed ID: 10487708
[TBL] [Abstract][Full Text] [Related]
10. Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine.
Doknic M; Pekic S; Zarkovic M; Medic-Stojanoska M; Dieguez C; Casanueva F; Popovic V
Eur J Endocrinol; 2002 Jul; 147(1):77-84. PubMed ID: 12088923
[TBL] [Abstract][Full Text] [Related]
11. Acute effect of basic fibroblast growth factor on secretion of prolactin as assessed by the reverse hemolytic plaque assay.
Larson GH; Koos RD; Sortino MA; Wise PM
Endocrinology; 1990 Feb; 126(2):927-32. PubMed ID: 2105207
[TBL] [Abstract][Full Text] [Related]
12. Prolactin secretion from human prolactinomas perifused in vitro: effect of TRH, prostaglandin E1, theophylline, dopamine and dopamine receptor blockers.
Chihara K; Iwasaki J; Minamitani N; Kaji H; Kodama H; Fujita T; Shirataki K; Tamaki N; Matsumoto S
Acta Endocrinol (Copenh); 1984 Jan; 105(1):6-13. PubMed ID: 6421041
[TBL] [Abstract][Full Text] [Related]
13. Prolactin in men's health and disease.
Bolyakov A; Paduch DA
Curr Opin Urol; 2011 Nov; 21(6):527-34. PubMed ID: 21941183
[TBL] [Abstract][Full Text] [Related]
14. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas.
Caccavelli L; Feron F; Morange I; Rouer E; Benarous R; Dewailly D; Jaquet P; Kordon C; Enjalbert A
Neuroendocrinology; 1994 Sep; 60(3):314-22. PubMed ID: 7969790
[TBL] [Abstract][Full Text] [Related]
15. Structure-function correlations of growth hormone or/and prolactin-producing pituitary adenomas: an in vitro study with the reverse hemolytic plaque assay.
Thodou E; Kontogeorgos G; Kyrodimou E; Salla H; Ramyar L; Vamvassakis E; Piaditis G; Anagnostopoulos N; Tzanis S; Levedis A; Rologis D; Asa SL
J Endocrinol Invest; 1999 Oct; 22(9):671-80. PubMed ID: 10595830
[TBL] [Abstract][Full Text] [Related]
16. Alteration of G alpha subunits mRNA levels in bromocriptine resistant prolactinomas.
Caccavelli L; Morange-Ramos I; Kordon C; Jaquet P; Enjalbert A
J Neuroendocrinol; 1996 Oct; 8(10):737-46. PubMed ID: 8910802
[TBL] [Abstract][Full Text] [Related]
17. Prolactin secretion by mixed ACTH-prolactin pituitary adenoma cells in culture.
Yamaji T; Ishibashi M; Teramoto A; Fukushima T
Acta Endocrinol (Copenh); 1985 Apr; 108(4):456-63. PubMed ID: 2859725
[TBL] [Abstract][Full Text] [Related]
18. Effects of age and long term ovariectomy on prolactin secretion, as assessed by the reverse hemolytic plaque assay.
Sortino MA; Wise PM
Endocrinology; 1989 Jan; 124(1):90-6. PubMed ID: 2491812
[TBL] [Abstract][Full Text] [Related]
19. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
[TBL] [Abstract][Full Text] [Related]
20. Bioactive forms of serum lactogens: effects of treatment of prolactinoma patients with bromocriptine.
Rennie PS; Prior JC; Bruchovsky N; Gout PW
Clin Endocrinol (Oxf); 1985 Jan; 22(1):65-73. PubMed ID: 3978829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
